Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells

Fei Yang; Jian Zhang; Xinyou Zhang; Mengli Tian; Jingjing Wang; Liqing Kang; Huiying Qiu; Depei Wu

doi:10.2147/OTT.S189103

Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells

Onco Targets Ther. 2019 Mar 25:12:2187-2191. doi: 10.2147/OTT.S189103. eCollection 2019.

Authors

Fei Yang¹, Jian Zhang¹, Xinyou Zhang², Mengli Tian¹, Jingjing Wang¹, Liqing Kang³, Huiying Qiu¹, Depei Wu¹

Affiliations

¹ Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China, pursueyf08@126.com.
² Department of Hematology, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), Jinan University, Shenzhen, Guangdong Province, People's Republic of China.
³ Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China.

Abstract

Background: CD19-modified CAR-T cells greatly influence responses in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, recurrence remains a challenge, and reinfusion of CAR-T cells is not always effective. Sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells may overcome this issue and induce remission.

Methods: We examined treatment with sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells in a patient with relapsed ALL previously exposed to murine-derived anti-CD19 CAR-T cells.

Results: At ~6 weeks after treatment, repeated bone marrow smear and flow cytometry analysis revealed no lymphoblasts.

Conclusion: Our results suggest that sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells is a valuable option for relapsed patients with prior infusion of murine-derived, CD19-directed CAR-T cells.

Keywords: acute lymphoblastic leukemia; anti-CD19; anti-CD22; chimeric antigen receptor; humanized; relapsed.